Compare Nucor Corporation (NUE) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs Smith & Nephew plc — how do they compare? Nucor Corporation trades at $250.33 (market cap $55.84B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Nucor Corporation is far larger — about 5× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Nucor Corporation for 78 Days and Smith & Nephew plc for 121 Days on average.
| NUE | SNN | |
|---|---|---|
Market Cap | $55.84B | $11.10B |
Volume | 848,835 | 1,051,703 |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $37.17 |
52-Week Low | $131.78 | $26.42 |
Typical Hold Time | 78 Days | 121 Days |
Enterprise Value | $60.25B | $14.13B |
Dividend Yield | 0.91% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $246.14, down 0.12% on the day, with a bearish technical signal despite recent earnings beats. The stock shows mixed sentiment with a moderate buy analyst consensus and a $266.88 price target. Revenue rebounded to $32.49B in 2025, though net margins have compressed from 2022 peaks. Recent news highlights steel sector volatility and Nucor's Q3 2026 guidance projecting higher earnings on improved pricing.
Outlook remains cautiously optimistic with earnings growth potential from steel price strength and operational efficiency, balanced by competitive pressures from new capacity and cyclical demand risks. The stock offers value at a P/E of 19.64 and a solid dividend history, but investors face headwinds from margin pressure and industry competition.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
